latest news releases from the newsroom
CombiMatrix Announces the Acceptance of Its Multi-Institute Study On the Use of HemeScan for CLL by Journal, Expert Opinions in Molecular Diagnostics
MUKILTEO, Wash., June 4, 2008 (PRIME NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that its subsidiary, Combimatrix Molecular Diagnostics (CMDX), has results from a multi-institute evaluation of its HemeScan(tm) test for CLL that were accepted for publication by the journal, Expert Opinions in Molecular Diagnostics (2008) 2(6): 1-10. The study, which was led by Dr. Shelly Gunn, Medical Director of CMDX, and which included collaborators from the prestigious M.D. Anderson Cancer Center, Texas, the Netherlands Cancer Institute, Amsterdam, and the University of Texas Health Science Center, San Antonio, evaluated over 170 patients with chronic lymphocytic leukemia (CLL) by the HemeScan test. The results of the study concluded that CMDX's HemeScan test is a powerful and cost-effective tool for genome-wide risk assessment in the clinical evaluation of CLL.
Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. Signs Consulting Agreement With Well Known Scientist, Dr. Donald Jarvis
LANSING, Mich., June 4, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) announced today that Dr. Donald Jarvis of the University of Wyoming has entered into a formal consulting relationship with the Company. Earlier this year Dr. Jarvis joined Kraig's Board of Scientific Advisors. Dr. Jarvis's appointment to the advisory board was made in anticipation of his entering into this consulting agreement. Dr. Jarvis will retain his position on the advisory board.